SG11201901594RA - Cell suspension for use in the treatment of lower extremity peripheral artery disease - Google Patents

Cell suspension for use in the treatment of lower extremity peripheral artery disease

Info

Publication number
SG11201901594RA
SG11201901594RA SG11201901594RA SG11201901594RA SG11201901594RA SG 11201901594R A SG11201901594R A SG 11201901594RA SG 11201901594R A SG11201901594R A SG 11201901594RA SG 11201901594R A SG11201901594R A SG 11201901594RA SG 11201901594R A SG11201901594R A SG 11201901594RA
Authority
SG
Singapore
Prior art keywords
international
cell suspension
sevilla
cartuja
calle
Prior art date
Application number
SG11201901594RA
Inventor
Jonathan Robert Barclay Dupere
Jong Liesbeth De
Edwin J Wagena
Original Assignee
Rexgenero Biosciences S L
Servicio Andaluz De Salud
Fund Publica Andaluza Progreso Y Salud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rexgenero Biosciences S L, Servicio Andaluz De Salud, Fund Publica Andaluza Progreso Y Salud filed Critical Rexgenero Biosciences S L
Publication of SG11201901594RA publication Critical patent/SG11201901594RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 March 2018 (01.03.2018) W I PO I PCT ill~~~~~~~~ 011101110VIIIOH olo oui olow mina° oimIE (10) International Publication Number WO 2018/037134 Al (51) International Patent Classification: C12N 5/078 (2010.01) C12N 5/0789 (2010.01) (21) International Application Number: PCT/EP2017/071580 (22) International Filing Date: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (25) Filing Language: (26) Publication Language: (30) Priority Data: 16382405.5 28 August 2017 (28.08.2017) English English 26 August 2016 (26.08.2016) EP Published: — with international search report (Art. 21(3)) (71) Applicants: REXGENERO BIOSCIENCES, S.L. [ES/ES]; Calle Max Planck 3, (Ed. Iris II, Isla de la Cartuja), 41092 Sevilla (ES). SERVICIO ANDALUZ DE SALUD [ES/ES]; Avda. de la Constitucion, 18, 41071 Sevilla (ES). FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD [ES/ES]; Avda. Americo Vespucio, 15, Edificio S2., Parque Cientifico y Tecnologico Cartuja, 41092 Sevil- la (ES). = (72) Inventors: DUPERE, Jonathan Robert Barclay; Rex- genero Biosciences S.L., Calle Max Planck 3., (Ed. Iris II, Isla de la Cartuja), 41092 Sevilla (ES). DE JONG, LIes- beth; Rexgenero Biosciences S.L., Calle Max Planck 3., (Ed. Iris II, Isla de la Cartuja), 41092 Sevilla (ES). WA- GENA, Edwin J; Rexgenero Biosciences S.L., Calle Max Planck 3., (Ed. Iris II, Isla de la Cartuj a), 41092 Sevilla (ES). (74) Agent: HOFFMANN EITLE, S.L.U.; Paseo de la Castel- lana 140, Planta 3', Edificio Lima, 28046 Madrid (ES). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (54) Title: CELL SUSPENSION FOR USE IN THE TREATMENT OF LOWER EXTREMITY PERIPHERAL ARTERY DISEASE (57) : The present invention refers to a cell suspension of autologous or allogeneic, preferably autologous, adult bone mar- row-derived white blood cells, preferably derived from the crest of the ilium (or iliac crest), enriched for mononuclear cells, meaning more than 25% of the white blood cells (WBCs) present in the cell suspension are mononuclear cells, and comprising: A.Mononuclear cells (MNC) selected from the list comprising or consisting of: i. A population of Lymphocytes; ii. A population of Monocytes; and iii. A population of Hematopoietic stem cells expressing CD34; and wherein the cell suspension further comprises: B.Granulocytes; for use in the treatment or amelioration of lower extremity peripheral artery disease. 1-1 N O co O C
SG11201901594RA 2016-08-26 2017-08-28 Cell suspension for use in the treatment of lower extremity peripheral artery disease SG11201901594RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16382405 2016-08-26
PCT/EP2017/071580 WO2018037134A1 (en) 2016-08-26 2017-08-28 Cell suspension for use in the treatment of lower extremity peripheral artery disease

Publications (1)

Publication Number Publication Date
SG11201901594RA true SG11201901594RA (en) 2019-03-28

Family

ID=56842774

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201901594RA SG11201901594RA (en) 2016-08-26 2017-08-28 Cell suspension for use in the treatment of lower extremity peripheral artery disease

Country Status (14)

Country Link
US (2) US10869886B2 (en)
EP (1) EP3504322A1 (en)
JP (2) JP7260878B2 (en)
KR (1) KR20190053198A (en)
CN (1) CN110168077B (en)
AU (1) AU2017315174B2 (en)
BR (1) BR112019003543A2 (en)
CA (1) CA3035076A1 (en)
EA (1) EA201990583A1 (en)
MX (1) MX2019002288A (en)
SA (1) SA519401187B1 (en)
SG (1) SG11201901594RA (en)
WO (1) WO2018037134A1 (en)
ZA (1) ZA201901826B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9402707B2 (en) 2008-07-22 2016-08-02 Neuravi Limited Clot capture systems and associated methods
EP2629684B1 (en) 2010-10-22 2018-07-25 Neuravi Limited Clot engagement and removal system
US11253278B2 (en) 2014-11-26 2022-02-22 Neuravi Limited Clot retrieval system for removing occlusive clot from a blood vessel
CN110168077B (en) * 2016-08-26 2024-06-14 雷克斯吉尼罗生物科学公司 Cell suspension for treating peripheral arterial disease of lower limb
US10842498B2 (en) * 2018-09-13 2020-11-24 Neuravi Limited Systems and methods of restoring perfusion to a vessel
US11406416B2 (en) 2018-10-02 2022-08-09 Neuravi Limited Joint assembly for vasculature obstruction capture device
US11871946B2 (en) 2020-04-17 2024-01-16 Neuravi Limited Clot retrieval device for removing clot from a blood vessel
US11937836B2 (en) 2020-06-22 2024-03-26 Neuravi Limited Clot retrieval system with expandable clot engaging framework
US11439418B2 (en) 2020-06-23 2022-09-13 Neuravi Limited Clot retrieval device for removing clot from a blood vessel
US11395669B2 (en) 2020-06-23 2022-07-26 Neuravi Limited Clot retrieval device with flexible collapsible frame
CN114561352A (en) * 2022-03-24 2022-05-31 青岛市中心血站 Method for separating mononuclear cells from blood donation complete blood collection device
WO2024099865A1 (en) * 2022-11-08 2024-05-16 Servicio Andaluz De Salud Cell suspension for use in the treatment of stroke patients

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110076255A1 (en) * 2005-11-07 2011-03-31 Pecora Andrew L Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
JP6105846B2 (en) 2008-09-12 2017-03-29 クライオプラキス クライオバイオロヒア エリテーデーアー． Cell therapy of ischemic tissue
US20150157663A1 (en) 2012-01-19 2015-06-11 Snu R&Db Foundation Pharmaceutical Composition Comprising Human-Blood-Derived-Cell Mass
US20130216495A1 (en) 2012-02-21 2013-08-22 Baxter Healthcare Sa Pharmaceutical composition comprising cd34+ cells
CN110168077B (en) * 2016-08-26 2024-06-14 雷克斯吉尼罗生物科学公司 Cell suspension for treating peripheral arterial disease of lower limb

Also Published As

Publication number Publication date
EA201990583A1 (en) 2019-08-30
CA3035076A1 (en) 2018-03-01
CN110168077B (en) 2024-06-14
US20210161960A1 (en) 2021-06-03
BR112019003543A2 (en) 2019-05-21
KR20190053198A (en) 2019-05-17
AU2017315174A1 (en) 2019-04-18
US20180055884A1 (en) 2018-03-01
JP2019528325A (en) 2019-10-10
SA519401187B1 (en) 2023-01-09
MX2019002288A (en) 2019-09-18
CN110168077A (en) 2019-08-23
JP2022166251A (en) 2022-11-01
ZA201901826B (en) 2019-12-18
AU2017315174B2 (en) 2023-11-09
EP3504322A1 (en) 2019-07-03
JP7260878B2 (en) 2023-04-19
US10869886B2 (en) 2020-12-22
WO2018037134A1 (en) 2018-03-01

Similar Documents

Publication Publication Date Title
SG11201901594RA (en) Cell suspension for use in the treatment of lower extremity peripheral artery disease
SG11201904535VA (en) Prevention and treatment of bone and cartilage damage or disease
SG11201907857RA (en) Edible and biodegradable utensils
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201810161RA (en) Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases
SG11201804070XA (en) Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
SG11201811048UA (en) Single-cell transcript sequencing
SG11201901494UA (en) Acid-alpha glucosidase variants and uses thereof
SG11201807913XA (en) Stabilized soluble pre-fusion rsv f proteins
SG11201811706RA (en) Process for the preparation of microcapsules
SG11201807041PA (en) Improved preparations of adult liver progenitor cells
SG11201808710UA (en) Novel immunogenic cd1d binding peptides
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201809534UA (en) Methods of treating autoimmune disease using allogeneic t cells
SG11201408808WA (en) Method and system for treatment of biological tissue
SG11201805001UA (en) Method of treating influenza a
SG11201908472VA (en) Compositions and methods for activating nk cells
SG11201909501TA (en) Personalized 3d neural culture system for generating human oligodendrocytes and studying myelination in vitro
SG11201805311XA (en) Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
SG11201808592PA (en) Method for selection of high m6p recombinant proteins
SG11201805771XA (en) Systems and methods for preparation of platelets
SG11201407405VA (en) Method for identifying ligands of the ahr receptor having therapeutic sebosuppressive activity, and said ligands
SG11201903770UA (en) Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
SG11201810078PA (en) Stabilized pre-fusion rsv f proteins
SG11201908275XA (en) Peptides and methods for the treatment of diabetes